Evidence map›Paper›PMID 34130119›Full record

ReviewJournal of infection and public health2021

The immunological response among COVID-19 patients with acute respiratory distress syndrome.

Abdulaziz S Almutairi, Hassan Abunurah, Abdulkarim Hadi Alanazi, Faraj Alenazi, Hassan Nagy, Nafea Saad Almutairi, Michael Wells, Abdullah Alawam, Mohammed M Alqahtani

Abstract readReview
In one paragraph

Review in Journal of infection and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Potential Drugs in COVID-19 Management.Current medicinal chemistry · 2024
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abdulaziz S AlmutairiFaculty Member at King Saud Abdul-Aziz University for Health Sciences, Riyadh, Saudi Arabia; School of Biomedical Science, University of Alabama at Birmingham, Birmingham, AL, United States; King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia. Electronic address: aziiz@uab.edu.
Hassan AbunurahFaculty Member at King Saud Abdul-Aziz University for Health Sciences, Riyadh, Saudi Arabia; Department of Rehabilitation Science, School of Health Profession, University of Alabama at Birmingham, Birmingham, AL, United States; King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia. Electronic address: hassan01@uab.edu.
Abdulkarim Hadi AlanaziFaculty Member at King Saud Abdul-Aziz University for Health Sciences, Riyadh, Saudi Arabia.
Faraj AlenaziFaculty Member at King Saud Abdul-Aziz University for Health Sciences, Riyadh, Saudi Arabia; University of Birmingham, Birmingham, United Kingdom; King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia.
Hassan NagyFairfax County Health Department, Fairfax, VA, United States.
Nafea Saad AlmutairiUniversity of Imam Muhammed ibn Saud, Riyadh, Saudi Arabia.
Michael WellsDivision of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham (UAB), United States.
Abdullah AlawamAl-Imam Muhammed ibn Saud Islamic University, Saudi Arabia.
Mohammed M AlqahtaniFaculty Member at King Saud Abdul-Aziz University for Health Sciences, Riyadh, Saudi Arabia; Department of Rehabilitation Science, School of Health Profession, University of Alabama at Birmingham, Birmingham, AL, United States; King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia. Electronic address: qahtani4@uab.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) often results in pneumonia and can lead to acute respiratory distress syndrome (ARDS). ARDS is one of the most significant causes of death in patients with COVID-19. The development of a "cytokine storm" in patients with COVID-19 causes progression to ARDS. In this scoping review, we investigated the effect of pro-inflammatory cytokines in inducing moderate and severe ARDS outcomes. A comprehensive search was performed using PubMed and Google Scholar to implement a broad query that captured all the relevant studies published between December 2019 and September 2020.We identified seven studies that evaluated the immune response in COVID-19 patients with ARDS. The white blood cell counts (WBCs), CRP, and IL-6 were higher in the moderately presenting ARDS patients, critically ill patients, and those with more severe ARDS. This study may contribute to better patient management and outcomes if tailored immune marker interventions are implemented in the near future.

Indexed as

COVID-19Respiratory Distress SyndromeCytokine Release SyndromeCytokinesHumansSARS-CoV-2CytokinesARDSCOVID-19cytokinesImmunological response

Identifiers

PMID34130119
PMCPMC8153960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.